MAPT and amyloidosis: Phospho-tau217 (p-tau217) has emerged as one of the most promising blood-based biomarkers for AD based on its diagnostic performance,10 strong correlations with amyloid and tau pathologies,11, 12, 13, 14 and equivalence with established CSF biomarkers in head-to-head studies.12